Utility of the Phoenix-8 and PELOD-2 scales in pediatric patients with sepsis and acute lymphoblastic leukemia admitted to a pediatric intensive care unit at a quaternary-level hospital in Bogotá, Colombia, 2022–2024
Abstract
Introduction: Sepsis in children with acute lymphoblastic leukemia (ALL) is associated with high mortality and a frequent need for advanced organ support; therefore, reliable scoring systems are required to stratify risk in the pediatric intensive care unit (PICU). Objective: To compare the performance of the Phoenix-8 and PELOD-2 scales, measured at 24 and 72 h after admission, for predicting 28-day mortality in children with ALL and sepsis or septic shock. Methods: A retrospective cohort study including 61 patients aged 1 month to 18 years with ALL admitted to the PICU of a quaternary-level hospital in Bogotá, Colombia, between 2022 and 2024. Phoenix-8 and PELOD-2 scores were calculated at 24 and 72 h after admission. Receiver operating characteristic (ROC) curves, optimal cutoff points, sensitivity, and specificity were analyzed. Results: Twenty-eight-day mortality was 23.0%; 27.9% of patients required invasive mechanical ventilation and 63.9% required vasoactive support. At 72 h, a PELOD-2 score ≥7 showed an area under the ROC curve (AUC) of 0.945, with a sensitivity of 92.9% and specificity of 91.1%. A Phoenix-8 score ≥8 achieved an AUC of 0.976, with a sensitivity of 92.9% and specificity of 91.3%, and was significantly associated with the use of mechanical ventilation, vasoactive agents, and renal replacement therapy. Discussion: Phoenix-8 and PELOD-2 demonstrated moderate discriminative ability at admission but excellent performance at 72 h, making them clinically useful and comparable tools for prognostic stratification in children with ALL and sepsis.
Fields of Study & Subjects
Sepsis Diagnosis and Treatment
Neutropenia and Cancer Infections
Inflammation biomarkers and pathways
Publication details
- Journal / source
- Frontiers in Pediatrics
- Volume
- 14
- Pages
- 1766687–1766687
- Publication date
- 18 February 2026
- Language
- EN